Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this ...

Please provide your email address to receive an email when new articles are posted on . Dabigatran is an oral anticoagulant - a synthetic thrombin inhibitor – that is approved in the United States for ...

Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically ...

Dabigatran etexilate (dabigatran) is a novel, oral, reversible, direct thrombin inhibitor that exhibits several advantages over warfarin for therapeutic anticoagulation. The predictable ...

Ascend Laboratories has recalled 10 lots of Dabigatran Etexilate capsules, used to lower the risk of blood clots and strokes, after finding the nitrosamine in the drug was above the FDA’s acceptable ...

Approximately 1 in 4 patients with nonvalvular atrial fibrillation (A-fib) who are prescribed dabigatran do not take it as directed and are therefore at increased risk for adverse clinical events, ...

Ascend Laboratories, maker of generic dabigatran etexilate, is recalling 10 manufacturing lots of the oral anticoagulant because of an unacceptably high level of a possible carcinogen, according to a ...

The Appraisal Committee considered evidence submitted by the manufacturer of dabigatran etexilate for the prevention of venous thromboembolism (VTE) after hip or knee replacement surgery in adults and ...

Cryptogenic strokes constitute 20 to 30% of ischemic strokes, and most cryptogenic strokes are considered to be embolic and of undetermined source. An earlier randomized trial showed that rivaroxaban ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The parallel, open-label GIRAF trial randomly assigned ...

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of dabigatran etexilate for the prevention of VTE after elective total hip or knee replacement surgery in ...